Asset Details
Do you wish to reserve the book?
Role of fibrates and HMG-CoA reductase inhibitors in gallstone formation: Epidemiological study in an unselected population
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Role of fibrates and HMG-CoA reductase inhibitors in gallstone formation: Epidemiological study in an unselected population
Do you wish to request the book?
Role of fibrates and HMG-CoA reductase inhibitors in gallstone formation: Epidemiological study in an unselected population
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Conference Proceeding
Role of fibrates and HMG-CoA reductase inhibitors in gallstone formation: Epidemiological study in an unselected population
2001
Overview
Fibrate derivatives and HMG-CoA reductase inhibitors modify homeostasis of cholesterol. The aim of this study was to assess in an unselected population whether these hypolipidemic drugs are risk factors for cholelithiasis or, conversely, are protective agents. Both sexes, all socioeconomic categories, pregnant women, and cholecystectomized subjects were included. Clinical data collection and gallbladder ultrasonography were both carried out in a double-blind fashion. Fibrate derivatives were predominantly fenofibrate, HMG-CoA reductase inhibitors were simvastatin and pravastatin. On univariate analysis, age (>50 years), sex, and use of fibrates were found to be significantly related to the presence of cholelithiasis. Age, sex, and fibrate treatment remained independently correlated with the presence of gallstones on multivariate analysis. With fibrates, the relative risk for lithiasis was 1.7 (P = 0.04). The HMG-CoA reductase inhibitors were not associated with a protective effect on univariate analysis. Of the lipid-lowering drugs, only fibrate derivatives were found to increase the risk of gallstone formation.
Publisher
Springer,Springer Nature B.V
Subject
Anticholesteremic Agents - adverse effects
/ Anticholesteremic Agents - pharmacology
/ Biological and medical sciences
/ Cholelithiasis - chemically induced
/ Cholelithiasis - prevention & control
/ Female
/ Fenofibrate - adverse effects
/ Gastroenterology. Liver. Pancreas. Abdomen
/ Humans
/ Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects
/ Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology
/ Hypolipidemic Agents - adverse effects
/ Hypolipidemic Agents - pharmacology
/ Liver. Biliary tract. Portal circulation. Exocrine pancreas
/ Male
/ Pravastatin - adverse effects
